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Sodium channel blocking antiarrhythmic drugs have preferential 
effects on diseased, slowly conducting myocardium, and slowing of 
tachycardia caused by these drugs may result primarily from 
further prolongation of conduction time in slowly conducting 
tissue. In patients with sustained ventricular tachycardia, late 
potentials detected by signal-averaged electrocardiography (ECG) 
are thought to arise from slowly conducting ventricular myocar-
dium. This study tested the hypothesis that sodium channel 
blocking drugs selectively prolong the late potential, or terminal 
low amplitude signal, portion of the signal-averaged QRS complex 
and that prolongation of the late potential would correlate with 
slowing of ventricular tachycardia. 
Fifty-six drug trials in 32 patients with spontaneous and 
inducible ventricular arrhythmias were studied. Prolongation of 
the late potential (11 ± 15 ms) was significantly greater than 
Late potentials are low amplitude, high frequency termi-
nal extensions of the QRS complex and can be detected by 
signal-averaged electrocardiography (ECG) in the majority 
of patients with spontaneous and inducible ventricular 
tachyarrhythmias (1-3). Late potentials are thought to arise 
from diseased, slowly conducting regions of the ventricular 
myocardium. It is possible that late potentials arise specifi-
cally from myocardium that participates in reentrant tachy-
cardia as the slowly conducting limb; however, there is no 
direct evidence for this and alternatively it is possible that 
late potentials reflect more global ventricular disease, only a 
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prolongation of the initial portion of the QRS complex (4 ± 9 ms) 
(p = 0.01). Selective prolongation of the late potential by drugs 
resulted in significantly greater QRS prolongation detectable by 
signal-averaged ECG than by standard ECG (p < 0.0001). In 40 
trials in which ventricular tachycardia remained inducible during 
drug therapy, the increase in induced tachycardia cycle length 
correlated strongly with the increase in late potential duration 
(p = 0.005) but not with change in the initial portion of the QRS 
complex. 
These data suggest that in patients with ventricular tachycar-
dia, sodium channel blocking antiarrhythmic drugs have prefer-
ential effects on slowly conducting tissue and that drug effect on 
slowly conducting tissue contributes to prolongation of ventricular 
tachycardia cycle length. 
(J Am Coil CardioI1991;17:1017-2S) 
small part of which, if any, participates in reentrant arrhyth-
mias. 
Antiarrhythmic drugs that block sodium channels result 
in prolongation of conduction time and may have a prefer-
ential effect on diseased, slowly conducting myocardium 
(4-7), possibly as a result of their enhanced effects on 
partially depolarized cells (8-10). Additionally, there is 
evidence (6,7) that tachycardia cycle length is prolonged by 
sodium channel blocking drugs primarily as a result of 
increased conduction time through diseased, slowly con-
ducting tissue. 
We hypothesized that in patients with spontaneous and 
inducible ventricular tachyarrhythmias, sodium channel 
blocking antiarrhythmic drugs would have selective effects 
on the late potential portion of the signal-averaged ECG and 
that these effects would correlate with changes in the rate of 
induced ventricular tachycardia. 
Methods 
Study patients. Electrophysiologic Study Versus Electro-
cardiographic Monitoring (ESVEM) (I1) is a multicenter 
trial sponsored by the National Institutes of Health to 
compare the accuracy of electrophysiologic study and 
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Table 1. Baseline Demographic, Cardiac and Electrophysiologic 
Characteristics of the 32 Study Subjects 
Gender 
Masculine 
Feminine 
Age (yr) (mean ± SO) 
Structural heart disease 
Coronary artery disease 
Idiopathic dilated cardiomyopathy 
Hypertensive cardiomyopathy 
Ejection fraction* (mean ± SO) 
Presenting arrhythmia or symptom 
Sustained ventricular tachycardia 
Ventricular fibrillation/cardiac arrest 
Syncopet 
Baseline electrophysiologic study 
Induced tachyarrhythmia cycle length (ms) 
*Oetermined in 29 patients; trhythm undocumented. 
27 (84%) 
5 (16%) 
60 ± 10 
27 (84%) 
4 (13%) 
1(3%) 
0.31 ± 0.10 
25 (78%) 
5 (\6%) 
2(6%) 
268 ± 66 
(range 180-490) 
Holter ECG monitoring in predicting antiarrhythmic drug 
efficacy in patients with spontaneous sustained ventricular 
tachyarrhythmias. All patients provided written informed 
consent according to the guidelines of the human subjects 
committees of the participating hospitals. Patients in this 
trial (11) are randomized to therapy assessment by electro-
physiologic study or Holter monitoring and undergo serial 
testing with drugs chosen randomly from a specified set of 
antiarrhythmic drugs. 
The subjects of this report are 32 patients qualifying for 
randomization in the ESVEM study who underwent signal-
averaged ECG at baseline (that is, in the absence of antiar-
rhythmic drug) and on at least one study drug. These 
patients were consecutively enrolled from the three ESVEM 
participating sites with the ability to obtain signal-averaged 
ECGs at the time of the study (University of Utah, 25 
patients; Columbia University, 5 patients; University of 
Oklahoma, 2 patients). The qualifying criteria for the 
ESVEM Study have been described previously (11) in detail 
and include: 1) at least one episode of spontaneous sustained 
(duration:::: 15 s) ventricular tachycardia (rate:::: 100 beats/ 
min) or fibrillation, aborted sudden death or unmonitored 
syncope, and 2) reproducibly (at least twice) inducible 
sustained (duration:::: 15 s) ventricular tachycardia or fibril-
lation at baseline electrophysiologic study. Patients with 
bundle branch block, although not excluded from ESVEM, 
were excluded from the present study. Table 1 summarizes 
baseline demographic, cardiac and electrophysiologic data 
for these 32 patients. Ejection fraction was determined by 
contrast or radio nuclide ventriculography. 
Electrophysiologic study. Baseline electrophysiologic 
study was performed after discontinuing antiarrhythmic 
drugs for at least five half-lives of drug and any active 
metabolites. Eiectrophysiologic study was performed ac-
cording to a rigid stimulation sequence (11). Stimulus dura-
tion was 2 ms and current was twice diastolic threshold. The 
protocol for ventricular arrhythmia induction began with 
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pacing at the right ventricular apex that used in sequence a 
single extrastimulus during sinus rhythm, two extrastimuli 
during sinus rhythm, one extrastimulus after ventricular 
drive and two extrastimuli after ventricular drive. The pro-
tocol then continued at the right ventricular outflow tract 
with one, two and three extrastimuli after ventricular drive. 
The final step in the sequence was three extrastimuli after 
ventricular drive at the right ventricular apex. Drive cycle 
lengths were 600, 500 and 400 ms. Coupling intervals of 
extrastimuli were started at 400 ms and were decremented 
by 10 ms until refractoriness was reached. The coupling 
interval was kept at 10 ms above the refractory period when 
a subsequent extrastimulus was introduced. Each combina-
tion of extrastimuli was delivered twice before any change in 
coupling interval was made. This stimulation protocol was 
followed until sustained (duration:::: 15 s) ventricular tachy-
cardia (rate :::: 100 beats/min) or ventricular fibrillation was 
induced twice. 
Follow-up electrophysiologic study was performed in 43 
of the 56 drug trials, but was not performed in the remaining 
13 trials because these were evaluated solely by Holter 
monitoring according to the ESVEM protocol randomization 
of the patients included in this report. The stimulation 
protocol used for the follow-up study was identical to that 
used for the baseline study. If ventricular arrhythmias had 
been induced with one or two extrastimuli during the base-
line study, three extrastimuli were not used during the 
follow-up study. The end point of stimulation for the fol-
low-up study was the induction of :::: 15 beats of ventricular 
tachycardia (rate :::: 100 beats/min) or completion of the 
protocol. 
Tachycardia cycle length was measured using hand-held 
calipers from the recorded ventricular electrograms 
(100 mm/s). Discrete ventricular electrograms were recorded 
during all episodes of induced ventricular tachyarrhythmia. 
Cycle lengths from 10 consecutive cycles were averaged in 
cases of irregular tachycardias. When more than a single 
episode of tachycardia was induced, the cycle length used 
for data analysis was the average of the measured cycle 
lengths. 
Signal-averaged ECG. A baseline signal-averaged ECG 
was recorded at least five half-lives after the last dose of an 
antiarrhythmic drug and within 48 h of baseline electrophys-
iologic study. A follow-up signal-averaged ECG was re-
corded after steady state had been reached on the final 
dosage of the drug and within 24 h of the follow-up electro-
physiologic study, if one was performed. A Corazonix 
Predictor or an Arrhythmia Research Technology model 
1200EPX was used for the recordings and analysis. Three 
bipolar signals were simultaneously recorded and digitized at 
2 kHz. The X lead was recorded between the left midaxillary 
line at the fifth intercostal space (positive) and the right 
midaxillary line at the fifth intercostal space (negative). The 
Y lead was recorded between the left anterior superior iliac 
spine (positive) and the suprasternal notch (negative). The Z 
lead was recorded between standard precordial lead V 2 
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position (positive) and a position directly posterior to V 2 
(negative). Two hundred to 600 beats were averaged. Final 
noise levels (zero mean standard deviation (SD) of all three 
leads within a 5 ms window in the TP segment) were 0.2 to 
0.5 /LV. 
Averaged X, Y and Z recordings were filtered with use of 
a bidirectional four pole Butterworth high pass digital filter 
with 40 Hz corner frequency (1). Filtered X, Y and Z 
recordings were combined into a single filtered QRS com-
plex according to the formula (X2 + y2 + Z2) 112. 
Onset and offset of the filtered QRS complex were 
determined automatically as the points where the signal 
exceeded three times the SD of noise levels at the beginning 
and end of the signal, respectively. The signal-averaged 
QRS duration was the difference between QRS onset and 
offset. The terminal low amplitude signal duration was 
defined as the duration of the terminal filtered QRS complex 
not <40 /LV (2). The initial QRS duration was defined as the 
duration of the QRS complex preceding the low amplitude 
signal. 
Standard ECG. The ESVEM protocol does not require 
submission of standard 12 lead ECGs, but they were avail-
able for review for all 32 patients at baseline study and for 46 
(82%) of the 56 drug trials. Standard ECGs were recorded at 
standard gain (10 mm/mV) and standard paper speed 
(25 mmls). The QRS duration was determined visually and 
with hand-held calipers in multiples of 10 ms as the longest 
duration of the QRS complex of the six limb lead recordings. 
Drug selection and dosage. Five sodium channel blocking 
antiarrhythmic drugs were in use in ESVEM at the time the 
present study was conducted: quinidine, procainamide, 
mexiletine, imipramine and propafenone. For all drugs but 
propafenone, final dosage was guided by target serum levels 
as follows: quinidine (2 to 6 /Lg/mi) , procainamide (4 to 
12 /Lg/mi), mexiletine (1 to 2 /Lg/mi) and imipramine (0.1 to 
OJ /Lg/ml) (sum of imipramine and desmethylimipramine 
levels). The target dose of propafenone was 6.4 to 12.9 mg/kg 
per day. Drug assessment was performed after steady state 
had been reached by the drug and its active metabolites on 
the final dose. Steady state was assumed to have occurred 
after 48 h for all drugs except procainamide, for which 
steady state was assumed at 24 h (all patients had a serum 
creatinine level <2.2 mg/dl and no patient had significant 
hepatic dysfunction). Trough (within 60 min before a dose) 
serum drug levels were determined at steady state on the 
same dosage the patient was receiving at the time of fol-
low-up signal-averaged ECG and electrophysiologic study 
(Table 2). 
Statistics. Values are expressed as mean values ± SD. 
Samples of continuous variables are compared using paired 
or unpaired Student's t statistic. All p values assume a 
two-tailed hypothesis. Correlations between continuous var-
iables were tested with use of the Pearson correlation 
coefficient (r). A statistic was considered significant if 
associated with a p value <0.05; however, larger p values 
are indicated to indicate trends. 
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Table 2. Drug Doses and Serum Levels in 56 Drug Trials 
Trough 
No. of Dose Serum Level 
Trials (mg/day) (JLg/ml) 
Propafenone 12 1,002 ± 254 1.2 ± 0.9 
Quinidine 7 2,367 ± 928 3.1 ± 0.8 
Procainamide 13 4,846 ± 1,573 8.0 ± 1.6 
Imipramine 13 261 ± 124 0.21 ± 0.07* 
Mexiletine 11 914 ± 217 1.4 ± 0.4 
*Sum of imipramine and desmethylimipramine levels. 
Results 
Comparison of changes in total QRS, initial QRS and late 
low amplitude signal at baseline and during drug therapy 
(Table 3, Fig. 1). The absolute increment in low amplitude 
signal duration (11 ± 15 ms) constituted 73% of the absolute 
increment in total QRS duration (15 ± 14 ms) and was 
significantly greater than the increment in initial QRS dura-
tion (4 ± 9 ms) (p = 0.01). Similarly, the fractional increase 
in low amplitude signal duration (30 ± 48%) exceeded the 
fractional increase in total QRS duration (13 ± 10%) and the 
fractional increase in initial QRS duration (6 ± 12%) (p = 
0.01 and p = 0.004, respectively). Prolongation of the low 
amplitude signal exceeded that of the initial QRS duration 
for all drugs studied except mexiletine (Table 3), for which 
the prolongation of total QRS duration was much less than 
for the other drugs. Differences in the extent of low ampli-
Table 3. Effects of Drugs on Signal-Averaged Electrocardiogram 
Measurements (ms) 
Baseline Drug Increment p Value 
Propafenone (n = 12) 
Total QRS 136 ± 20 165 ± 24 29 ± 17 0.0001 
Initial QRS 76 ± 14 82 ± 14 5 ± 15 0.2 
LAS 60 ± 25 84 ± 27 24 ± 19 0.001 
Quinidine (n = 7) 
Total QRS 133 ± 22 147 ± 27 14 ± 6 0.0007 
Initial QRS 73 ± 3 75± 7 2 ± 6 0.4 
LAS 60 ± 27 72 ± 28 12 ± 7 0.005 
Procainamide (n = 13) 
Total QRS 131 ± 24 146 ± 28 15 ± 10 0.0003 
Initial QRS 76 ± 11 80 ± 11 3 ± 9 0.2 
LAS 55 ± 25 67 ± 27 12 ± 14 0.01 
Imipramine (n = 13) 
Total QRS 133 ± 17 143 ± 20 10 ± 12 0.01 
Initial QRS 79 ± 16 83 ± 15 4 ± 10 0.2 
LAS 54 ± 21 60 ± 23 6 ± 12 0.07 
Mexiletine (n = 11) 
Total QRS 133 ± 13 138 ± 14 5 ± 9 0.1 
Initial QRS 72 ± 9 76 ± \0 3 ± 3 0.2 
LAS 61 ± 16 62 ± 15 1 ± 3 0.6 
Total (n = 56) 
Total QRS 133 ± 19 148 ± 24 15 ± 14 <0.0001 
Initial QRS 76 ± 12 79 ± 12 4 ± 9 0.006 
LAS 57 ± 22 69 ± 25 11 ± 15 <0.0001 
LAS = late low amplitude signal. 
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Figure 1. Duration of initial QRS complex and low amplitude signal 
(LAS) at baseline (top) and during drug therapy (bottom) in all 56 
drug trials. All values are in ms. Most of the increase in total 
signal-averaged QRS duration results from prolongation of the late 
low amplitude signal. 
tude signal prolongation among the drugs accounted for 
almost all of the differences in overall QRS prolongation. 
Prolongation of the initial QRS complex ranged only from 3 
to 5 ms among the drugs studied, whereas prolongation of 
low amplitude signal ranged from I to 24 ms, with pro-
pafenone resulting in the greatest low amplitude signal 
prolongation and mexiletine the least (Table 3). 
Changes in QRS duration on signal-averaged ECG com-
pared with changes in QRS duration on standard ECG (Table 
4). The average increase in QRS duration detected by the 
signal-averaged ECG during drug therapy was more than 
twice that detected by the standard ECG (Fig. 2, Table 4). 
The increase in signal-averaged QRS duration exceeded the 
increase in standard QRS duration by ~IO ms in 20 (43%) of 
the 46 drug trials (Fig. 3). In these 20 trials, prolongation of 
the low amplitude signal (19 ± 15 ms) was significantly 
greater than in the other 26 drug trials (6 ± 14 ms) (p = 0.005) 
(Fig. 4). Thus, selective prolongation of the low amplitude 
signal, which is not detectable by standard ECG, contributes 
to the greater prolongation of total QRS duration detected by 
signal-averaged compared with standard ECG. 
Most of the standard ECGs were performed with use of 
an electrocardiograph (Marquette Electronics) that automat-
ically measures QRS duration. Comparisons of standard 
QRS durations measured automatically at baseline study and 
during drug therapy were available for 37 trials. In these 37 
trials, the increment in standard QRS duration measured 
automatically (7.4 ± 11.9 ms) was less than the increment 
detected by signal-averaged ECG (13.4 ± 14.1 ms) (p = 0.02) 
Table 4. Comparison of QRS Durations Measured by Standard 
Versus Signal-Averaged Electrocardiography (ECG) 
Standard Signal-Averaged 
ECG ECG p Value 
QRS duration at 97 ± 15 130 ± 18 <0.0001 
baseline (ms) 
QRS duration on 104 ± 18 146 ± 24 <0.0001 
drug (ms) 
Increment (ms) 7 ± 10 16 ± 14 <0.0001 
50 
40 
CHANGE IN 30 
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Figure 2. Change in QRS duration detected by signal-averaged 
electrocardiogram (ECG) resulting from antiarrhythmic drugs com-
pared with change in QRS duration detected by standard ECG. Most 
o~ the points lie above the line of identity (arrow), indicating that the 
SIgnal-averaged ECG detects more QRS prolongation than does the 
standard ECG (p < 0.0001 by paired t test). All values are in ms. 
and not significantly different from that detected manually on 
the standard ECG (5.1 ± 9.0 ms). 
Relation to effects of drugs on induced and spontaneous 
arrhythmias. Electrophysiologic study was performed in all 
32 patients at baseline, and the cycle length of the induced 
ventricular tachyarrhythmia was 268 ± 66 ms. No significant 
correlation was found between baseline induced tachycardia 
cycle length and baseline signal-averaged QRS duration or 
low amplitUde signal duration. Follow-up electrophysiologic 
study was performed for 43 of the 56 drug trials. Of these, 
ventricular tachycardia of ~15 beats' duration was rein-
duced during 40 trials (20 patients); ventricular tachycardia 
was noninducible in just 3 drug trials included in this report. 
In the 40 drug trials in which ventricular tachycardia was 
reinduced, the cycle length of the induced arrhythmia was 
332 ± 57 ms, significantly greater than the tachycardia cycle 
length at baseline study (261 ± 49 ms) (p < 0.0001). There 
was a significant positive correlation between the increment 
in tachycardia cycle length associated with antiarrhythmic 
drug therapy and the increment in duration of the low 
amplitude signal portion of the signal-averaged ECG (p = 
0.005) (Fig. 5). The slope of the regression line relating the 
change in cycle length to the change in low amplitude signal 
was greater than unity, which indicates that on average the 
absolute prolongation of cycle length exceeded the absolute 
prolongation of the low amplitude signal. In contrast, there 
was no correlation between change in cycle length and 
prolongation of the initial portion of the signal-averaged QRS 
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Figure 3. An example of signal-averaged electrocardiogram (ECG), 
standard ECG and induced ventricular tachycardia in a patient at 
baseline (top) and during therapy with propafenone (bottom). The 
total QRS duration of each signal-averaged ECG is divided into an 
initial QRS portion and a low amplitude signal (LAS) portion; these 
two portions are demarcated by the point where the amplitude of the 
terminal QRS complex reaches 40 /LV (dashed line). Total signal-
averaged QRS duration increased from 151 ms at baseline study to 
177 ms during drug therapy. The 26 ms increase in total QRS 
duration comprised a 20 ms prolongation of low amplitude 
QRS 110 
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signal and only a 6 ms prolongation of initial QRS duration. The 
standard ECG detected only a 10 ms increase in QRS duration (from 
100 to 110 ms). Sustained ventricular tachycardia was induced with 
two ventricular extrastimuli after ventricular drive (arrows) in 
baseline state and on drug, and there was a large increase (115 ms) 
in tachycardia cycle length (CL) resulting from drug therapy. The 
large increase in tachycardia cycle length in this case was associated 
with a large prolongation of low amplitude signal, but only a small 
prolongation of the initial QRS duration and a small prolongation of 
QRS duration detected by standard ECG. 
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Figure 4. Changes in initial QRS duration and low amplitude signal 
(LAS) in 46 drug trials grouped by whether or not the increment in 
signal-averaged electrocardiographic (SAECG) QRS duration ex-
ceeded the increment in standard QRS duration by 2::10 ms. In the 
drug trials where the increment in signal-averaged QRS duration 
exceeded the increment in standard QRS duration by 2:: 10 ms 
(right), there is a large increase in low amplitude signal that 
significantly exceeds the increase in the low amplitude signal in trials 
where the increment in signal-averaged QRS duration was within 
to ms of the increment in standard QRS duration (left). Thus, 
selective prolongation of the low amplitude signal contributes to the 
greater QRS prolongation detected by signal-averaged ECG com-
pared with standard ECG. 
complex nor was there a correlation between the change in 
cycle length and prolongation of the QRS complex on 
standard ECG (Fig. 5). 
Ventricular tachycardia cycle length was prolonged 
> 100 ms in 10 (25%) of the 40 drug trials in which tachycar-
dia was reinduced. The increase in low amplitude signal in 
these 10 trials (18 ± 12 ms) was significantly greater than in 
the other 30 trials (6 ± II ms) (p = 0.007). The low amplitude 
signal was prolonged by ~5 ms in all 10 trials in which 
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tachycardia cycle length increased by> 100 ms, whereas the 
low amplitude signal failed to prolong ~5 ms in 15 (50%) of 
30 drug trials in which the increase in tachycardia cycle 
length was <100 ms. Thus, an increase in the low amplitude 
signal of ~5 ms identified patients whose tachycardia cycle 
length increased> 100 ms with a sensitivity of 100% (10 of 10 
trials), a specificity of 40% (10 of 25 trials) and an overall 
predictive accuracy of 63% (25 of 40) trials. 
Antiarrhythmic drugs prevented induction of ventricular 
tachycardia by strict ESVEM criteria in only three trials 
included in this report, so no meaningful analysis could be 
performed comparing trials with and without persistent 
arrhythmia inducibility. 
Discussion 
The principal findings of this study are that sodium 
channel blocking antiarrhythmic drugs selectively prolong 
the low amplitude, late potential portion of the signal-
averaged QRS complex and that the magnitude of late 
potential prolongation correlates with the increase in the 
cycle length of induced ventricular tachycardia. Further-
more, selective prolongation of the late potential accounts 
for part of the greater sensitivity of the signal-averaged ECG 
in detecting QRS prolongation compared with the standard 
ECG. 
Relation to selective drug effect on slowly conducting 
portions of the myocardium. It is thought that the late 
potential portion of the signal-averaged QRS complex arises 
from areas of the ventricular myocardium in which depolar-
ization is delayed and conduction is slow. The selective 
prolongation of the late potential by antiarrhythmic drugs 
observed in this study suggests that these drugs delay 
conduction more in myocardium where baseline conduction 
is slow than in myocardium where baseline conduction 
velocity is normal. Such conduction delay could result from 
a delay in the onset of local activation or a further prolon-
gation of conduction time, or both. 
Previous studies in canine infarct models have shown 
selective effects of sodium channel blocking antiarrhythmic 
drugs on abnormal myocardium. Patterson et al. (4) showed 
that lidocaine prolonged electrogram duration in infarcted 
tissue more than in noninfarcted tissue. DeLangen et al. (5) 
showed that procainamide resulted in more delay and pro-
longation among electrograms occurring late with respect to 
the QRS complex than among those electrograms occurring 
earlier. However, in a study in humans, Schmitt et al. (12) 
failed to detect a differential effect of antiarrhythmic drugs 
on normal versus abnormal electrograms. 
The mechanism whereby sodium channel blocking antiar-
rhythmic drugs may selectively influence diseased myocar-
dium is not known. Some studies (13-15) have shown re-
duced membrane potentials at rest in chronically infarcted 
myocardium, and selective effects of antiarrhythmic drugs in 
such tis~ue can be explained by the well known enhanced 
effects of antiarrhythmic drugs on partially depolarized cells 
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(8-10). However, a more recent study (16) found normal 
action potentials in chronically infarcted myocardium dis-
playing fractionated electrograms and slow conduction, and 
the electrophysiologic abnormalities of this tissue were 
postulated to result from abnormal cell to cell coupling. It is 
less clear why antiarrhythmic drugs might selectively affect 
myocardium with normal action potentials but impaired cell 
to cell coupling. 
Late potential duration and tachycardia cycle length. We 
found no correlation between baseline late potential duration 
and baseline ventricular tachycardia cycle length. There are 
several possible explanations for this finding. First, it is 
possible that late potentials arise predominantly from tissue 
not directly involved in reentrant circuits utilized during 
tachycardia. Second, it is possible that the tachycardia cycle 
length primarily is determined not by slowly conducting 
tissue, but rather by conduction around an anatomic obsta-
cle (17). Third, the degree of conduction slowing in tissue 
generating late potentials may be greatly different during 
tachycardia than during sinus rhythm. Finally, the late 
potential detectable by signal-averaged ECG probably rep-
resents only a portion of the slowly conducting area of 
myocardium; potentials from slowly conducting areas of the 
myocardium that are engaged early with respect to the QRS 
complex during sinus rhythm may be buried within the initial 
portion of the QRS complex and not contribute to the late 
potential, yet these areas may participate in reentrant tachy-
cardias. 
However, there was a significant correlation between the 
increase in late potential duration caused by antiarrhythmic 
drugs and the prolongation of ventricular tachycardia cycle 
length. This observation may indicate that portions of the 
presumed reentrant circuit respond to antiarrhythmic drugs 
Figure 5. Correlations between changes in cycle length of induced 
ventricular tachycardia and low amplitude signal (LAS) (left), initial 
QRS duration (middle) and QRS duration on the standard electro-
cardiogram (ECG) (right). The increase in cycle length correlated 
significantly with increases in low amplitude signal. There was no 
relation between the change in cycle length and the change in initial 
QRS duration or change in QRS duration on the standard ECG. 
in a quantitatively similar way to tissue generating late 
potentials, and it suggests that tissue generating late poten-
tials actually may constitute a portion of the reentrant 
circuit. Conversely, there was comparatively little effect of 
antiarrhythmic drugs on the initial portion of the signal-
averaged QRS complex. This finding suggests that slowing of 
tachycardia by drugs is not a result of drug effect on the 
presumably normally conducting tissue generating the initial 
portion of the signal-averaged QRS complex. 
The slope of the regression line relating prolongation of 
the tachycardia cycle length to prolongation of the late 
potential (Fig. 5) indicates that the absolute prolongation of 
tachycardia cycle length resulting from drugs tends to ex-
ceed the absolute prolongation of late potential duration. 
There are several possible explanations for this. First, pro-
longation of conduction time resulting from drugs is greater 
at faster heart rates, as suggested by the modulated receptor 
hypothesis of antiarrhythmic drug action (18). Second, pro-
longation of ventricular refractoriness resulting from antiar-
rhythmic drugs may contribute to slowing of tachycardia 
(19), and these changes in refractoriness may not be reflected 
by any change in late potential duration. Third, regions of 
slowly conducting myocardium that are depolarized simul-
taneously during sinus rhythm may form sequential compo-
nents of the presumed reentrant circuit. 
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There are other reports suggesting that changes in tachy-
cardia cycle length resulting from antiarrhythmic drugs 
result primarily from drug effect on slowly conducting tissue. 
Kay et al. (6) used entrainment techniques in five patients 
with ventricular tachycardia to demonstrate that procaina-
mide prolonged conduction times principally in the slowly 
conducting portion of the reentrant circuit and that the 
degree of this prolongation correlated with prolongation of 
tachycardia cycle length. By contrast, there was little effect 
of procainamide in normally conducting myocardium and 
there was no correlation between changes in normally con-
ducting myocardium and changes in tachycardia cycle 
length. Schoels et al. (7), using a canine model of atrial 
flutter, found that increases in flutter cycle length resulting 
from procainamide were primarily from the effect of procain-
amide on a zone of slow conduction and that procainamide 
had comparatively little effect on the other portions of the 
reentrant circuit. 
It has been suggested (20) that in patients with sustained 
tachyarrhythmias, therapy with drugs that prolong the cycle 
length of induced ventricular tachycardia by > 100 ms is 
associated with a favorable prognosis. In the current study, 
prolongation of the late potential by ~5 ms predicted such a 
prolongation in cycle length with a sensitivity of 100% and a 
specificity of 40%. It is possible that analysis of change in 
late potential duration could be used as a screening test to 
identify drug therapy resulting in large prolongations of 
tachycardia cycle length. 
Previous reports of effect of antiarrhythmic drugs on 
signal-averaged ECG. Prolongations of total QRS duration 
and late potential duration have been reported by most 
(5,21,22) but not all (23) authors studying the effects of 
antiarrhythmic drugs on time domain features of the signal-
averaged ECG. In a canine infarct model, de Langen et al. 
(5) demonstrated a greater prolongation by procainamide of 
the late potential portion of the QRS complex than of the 
initial portion of the QRS complex in a pattern similar to that 
demonstrated in the present study. DeLangen et al. (5) also 
performed epicardial recordings in their dogs before and 
after procainamide and found that selective prolongation of 
the late potential portion of the QRS complex coincided with 
selective delay of electrograms occurring later with respect 
to the QRS complex. Such a mechanism may have been 
operative in the patients in the present study. 
Several authors (21-24) have reported persistence of late 
potentials during drug therapy in patients with ventricular 
tachycardia regardless of whether the drugs prevented in-
duction of tachycardia. Thus, block of conduction into 
diseased tissue generating late potentials during sinus 
rhythm does not appear to be a prerequisite for prevention of 
tachycardia induction. These reports (21-24) did not exam-
ine quantitative relations between changes in the signal-
averaged QRS complex and changes in tachycardia cycle 
length. 
Limitations. We interpreted the results of the study using 
the assumption that the initial portion of the signal-averaged 
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QRS complex arises from normally conducting myocardium 
and the late potential, or low amplitude signal portion, arises 
from slowly conducting tissue. This assumption undoubtedly 
is an oversimplification. For example, slowly conducting 
tissue that is activated early during sinus rhythm may 
contribute primarily to the initial portion of the QRS com-
plex. Conversely, it is possible that late potentials arise in 
part from tissue that is activated late but has normal con-
duction properties. 
Implications. Application of the signal-averaged ECG for 
assessment of antiarrhythmic drug therapy has been limited 
and currently there is no clinical role for signal-averaged 
ECG for guidance of drug therapy. This study suggests that 
the signal-averaged ECG may provide information on the 
electrophysiologic effect of sodium channel blocking drugs 
on slowly conducting areas of the ventricular myocardium in 
patients with sustained ventricular tachyarrhythmias. 
Among patients with sustained ventricular tachyarrhyth-
mias, changes in late potential duration may be helpful in 
predicting changes in tachycardia cycle length resulting from 
drug therapy. In the future, the signal-averaged ECG may 
prove useful in noninvasively assessing other electrophysi-
ologic effects-both antiarrhythmic and proarrhythmic-of 
antiarrhythmic drugs. 
We acknowledge the expert technical expertise of Susan Lyver, RN, Deborah 
Barton, RN and Patricia Leahey and the expert secretarial assistance of 
Karen Allen. 
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